Erre Gian Luca, Bassu Stefania, Giordo Roberta, Mangoni Arduino A, Carru Ciriaco, Pintus Gianfranco, Zinellu Angelo
Dipartimento di Medicina, Chirurgia e Farmacia, Università degli Studi di Sassari, Viale San Pietro, 8, 07100 Sassari, Italy.
Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, 07100 Sassari, Italy.
Antioxidants (Basel). 2022 Nov 23;11(12):2317. doi: 10.3390/antiox11122317.
Background: A decrease in serum paraoxonase (PON-1) and arylesterase (ARE) activity has been reported in rheumatoid arthritis (RA) patients and linked to chronic inflammation and impaired antioxidant defense. Methods: A systematic review and meta-analysis were performed to critically appraise the current evidence on plasma/serum concentrations of PON-1 and ARE activity in RA patients and healthy controls. The Web of Science, PubMed, Scopus, and Google Scholar databases were searched from inception to November 2021. We used random-effects meta-analysis. The risk of bias was estimated using the Joanna Briggs Institute Critical Appraisal Checklist tool. The certainty of the evidence was assessed with GRADE. The study complied with the PRISMA statements and was registered in PROSPERO (CRD42022345380). Results: Seventeen studies reported PON-1 activity (1144 RA patients, 797 controls) and ten reported ARE activity (1367 RA patients, 1037 controls). RA patients had significantly lower PON-1 (SMD = −1.32, 95% CI −1.94 to −0.70; p < 0.001) and ARE activity (SMD = −0.91, 95% CI −1.37 to −0.46; p < 0.001). There was substantial heterogeneity (PON, I2 97%; ARE, 95.7%, p < 0.001 for both). There was no publication bias. The pooled SMD values did not significantly change after sensitivity analysis. The certainty of the evidence was very low due to the observational nature of the studies and the large heterogeneity. Conclusion: Our meta-analysis has shown that both serum PON-1 and ARE activity are significantly lower in RA patients, suggesting a deficit in antioxidant defense mechanisms in this disease.
据报道，类风湿关节炎（RA）患者血清对氧磷酶（PON - 1）和芳基酯酶（ARE）活性降低，且与慢性炎症和抗氧化防御受损有关。方法：进行了一项系统评价和荟萃分析，以严格评估目前关于RA患者和健康对照者血浆/血清中PON - 1浓度及ARE活性的证据。检索了Web of Science、PubMed、Scopus和谷歌学术数据库，检索时间从建库至2021年11月。我们采用随机效应荟萃分析。使用乔安娜·布里格斯研究所批判性评价清单工具评估偏倚风险。用GRADE评估证据的确定性。该研究符合PRISMA声明，并在PROSPERO（CRD42022345380）注册。结果：17项研究报告了PON - 1活性（1144例RA患者，797例对照），10项研究报告了ARE活性（1367例RA患者，1037例对照）。RA患者的PON - 1活性（标准化均数差[SMD]= - 1.32，95%可信区间[CI] - 1.94至 - 0.70；p < 0.001）和ARE活性（SMD = - 0.91，95% CI - 1.37至 - 0.46；p < 0.001）显著较低。存在显著异质性（PON，I² 97%；ARE，95.7%，两者p均< 0.001）。不存在发表偏倚。敏感性分析后，合并的SMD值无显著变化。由于研究的观察性性质和较大的异质性，证据的确定性非常低。结论：我们的荟萃分析表明，RA患者血清PON - 1和ARE活性均显著降低，提示该疾病抗氧化防御机制存在缺陷。
